12/16/2023 0 Comments Waves nx free trialHe currently sits on the Boards of BioNJ and Defender Pharmaceuticals. He began his career at Schering-Plough where he held executive roles both in the U.S. Oakes held several positions at Novartis, including Head of Sandoz Biopharmaceuticals, North America and Senior Vice President, Market Access and Primary Care. Oakes also helped steer the $74 billion acquisition by Bristol-Myers Squibb and the $13.4 billion divestiture of Otezla. Inflammation and Immunology, at Celgene from 2017 to 2019. Oakes served as Corporate Vice President and US General Manager, U.S. Previously, he served as Corporate Vice President and Global Integration Lead for Otezla® at Amgen from 2019 to 2020, overseeing the integration of the $2 billion brand acquired from Celgene, and positioning it for sustained growth. Prior to joining Landos, he served as President, North America, Executive Vice President and member of the Executive Committee of Vifor Pharma since 2020. Oakes has more than 25 years of experience creating value for small, mid-sized and large pharmaceutical companies. With new leadership in place and continued progress in the Board’s strategic review of Landos’ programs, we remain on track to provide a comprehensive update on our clinical development plans and progress later this year.”Ībout Gregory Oakes Mr. We look forward to continuing to benefit from his experience and insights as a member of our Board. Garabedian continued, “We thank Tim for his leadership over the last seven months in refocusing and reprioritizing Landos’ key initiatives and establishing a solid foundation for driving future value. I look forward to working with and growing Landos’ talented team to deliver on our mission of addressing the therapeutic gap for patients with autoimmune diseases.” I believe that Landos has the potential to change the lives of patients suffering from autoimmune diseases, and I’m excited about the tremendous clinical and commercial opportunities ahead of us. “With a promising pipeline of clinical-stage assets and a sharpened focus on pursuing the most promising target indications, Landos has a strong foundation in place. “I am honored to be joining Landos at such a pivotal time for the Company,” said Mr. We are excited to leverage Greg’s strong background in inflammation and immunology as we refine and finalize developments plans for our three clinical-stage product candidates – omilancor, NX-13 and LABP-104.” “Greg is an industry veteran with a proven track record of developing and commercializing innovative products for multiple therapeutic areas and delivering value for shareholders and patients alike. “Following a comprehensive and thoughtful search process, we are thrilled to name Greg as President and CEO of Landos,” said Chris Garabedian, Chairman of the Board. He also has extensive experience in pricing, access and reimbursement, strategic partnerships and driving profitability for small, mid-sized and large pharmaceutical companies. He brings deep expertise in supporting development stage programs, from optimizing clinical strategy and competitive positioning to achieving successful commercialization. He most recently served as President, North America, Executive Vice President and member of the Executive Committee of Vifor Pharma and previously held leadership roles at Amgen, Celgene Corporation, Novartis International AG and Schering-Plough (Merck). Oakes is an accomplished pharmaceutical industry executive bringing more than 25 years of experience to Landos. Mayleben, who has been serving as interim President and Chief Executive Officer since November 2021, will continue to serve as a member of the Company’s Board of Directors. ![]() (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that Gregory Oakes has been named President and Chief Executive Officer, and has been appointed to the Landos Board of Directors, effective immediately. NEW YORK, J(GLOBE NEWSWIRE) - Landos Biopharma, Inc. Seasoned Pharmaceutical Executive Brings 25+ Years of Experience With a Focus on Successful CommercializationĬompany Remains On Track to Complete Review of Clinical Development Plans Later This Year Claim your 1-week free trial to StreetInsider Premium here. Get instant alerts when news breaks on your stocks.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |